Promentis Pharmaceuticals Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 7

Promentis Pharmaceuticals General Information

Description

Developer of medical therapies designed to treat central nervous system disorders. The company's therapies are focused on activating a target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders, enabling healthcare practitioners to treat various psychiatric disorders.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 826 North Plankinton Avenue
  • Suite 400
  • Milwaukee, WI 53203
  • United States
+1 (414)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Corporate Office
  • 826 North Plankinton Avenue
  • Suite 400
  • Milwaukee, WI 53203
  • United States
+1 (414)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Promentis Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Secondary Transaction - Private 01-Mar-2026 Completed Generating Revenue
10. Later Stage VC 01-Nov-2020 Completed Generating Revenue
9. Debt - General 10-Dec-2019 Completed Clinical Trials - Phase 2
8. Later Stage VC (Series C) 04-Dec-2019 Completed Clinical Trials - Phase 2
7. Later Stage VC (Series C) 22-Sep-2017 Completed Pre-Clinical Trials
6. Grant 01-Jan-2015 Completed Pre-Clinical Trials
5. Later Stage VC (Series B) 31-Dec-2013 Completed Pre-Clinical Trials
4. Grant 28-Sep-2012 Completed Startup
3. Early Stage VC (Series A) 25-Feb-2010 $1.95M $2.2M Completed Startup
2. Debt - General 11-Feb-2010 $250K $250K Completed Startup
To view Promentis Pharmaceuticals’s complete valuation and funding history, request access »

Promentis Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B
Series A 2,224,536 $0.001000 8% $0.88 $0.88 1x $0.88 5.13%
To view Promentis Pharmaceuticals’s complete cap table history, request access »

Promentis Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of medical therapies designed to treat central nervous system disorders. The company's therapies are focused o
Drug Discovery
Milwaukee, WI
5 As of 2025

New York, NY
 

Toronto, Canada
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Promentis Pharmaceuticals Competitors (73)

One of Promentis Pharmaceuticals’s 73 competitors is Curemark, a Venture Capital-Backed company based in New York, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Curemark Venture Capital-Backed New York, NY
Lucid Psycheceuticals Corporate Backed or Acquired Toronto, Canada
Astrocyte Pharma Venture Capital-Backed Groton, CT
Aptinyx Formerly VC-backed Evanston, IL
Supernus Formerly VC-backed Rockville, MD
You’re viewing 5 of 73 competitors. Get the full list »

Promentis Pharmaceuticals Patents

Promentis Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20150344419-A1 Propionic acids, propionic acid esters, and related compounds Active 30-May-2014
US-9193681-B1 Propionic acids, propionic acid esters, and related compounds Inactive 30-May-2014
US-20150133544-A1 Ethyl (2r)-2-acetamido-3-(4-methylbenzoylsulfanyl)propanoate and uses thereof Active 08-Nov-2013
US-9012674-B1 Ethyl (2r)-2-acetamido-3-(4-methylbenzoylsulfanyl)propanoate and uses thereof Active 08-Nov-2013
AU-2014346591-A1 Substituted n-acetyl-l-cysteine derivatives and related compounds Active 08-Nov-2013 C07C327/34
To view Promentis Pharmaceuticals’s complete patent history, request access »

Promentis Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Promentis Pharmaceuticals Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Aisling Capital Venture Capital Minority
F-Prime Venture Capital Minority
OrbiMed Growth/Expansion Minority
Michael J. Fox Foundation Limited Partner
National Institute of Mental Health Government
You’re viewing 5 of 7 investors. Get the full list »

Promentis Pharmaceuticals FAQs

  • When was Promentis Pharmaceuticals founded?

    Promentis Pharmaceuticals was founded in 2007.

  • Where is Promentis Pharmaceuticals headquartered?

    Promentis Pharmaceuticals is headquartered in Milwaukee, WI.

  • What is the size of Promentis Pharmaceuticals?

    Promentis Pharmaceuticals has 5 total employees.

  • What industry is Promentis Pharmaceuticals in?

    Promentis Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Promentis Pharmaceuticals a private or public company?

    Promentis Pharmaceuticals is a Private company.

  • What is Promentis Pharmaceuticals’s current revenue?

    The current revenue for Promentis Pharmaceuticals is .

  • How much funding has Promentis Pharmaceuticals raised over time?

    Promentis Pharmaceuticals has raised $40.3M.

  • Who are Promentis Pharmaceuticals’s investors?

    Aisling Capital, F-Prime, OrbiMed, Michael J. Fox Foundation, and National Institute of Mental Health are 5 of 7 investors who have invested in Promentis Pharmaceuticals.

  • Who are Promentis Pharmaceuticals’s competitors?

    Curemark, Lucid Psycheceuticals, Astrocyte Pharma, Aptinyx, and Supernus are some of the 73 competitors of Promentis Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process